Filgotinib maleate (GLPG0634 maleate) is a selective, orally available JAK1 inhibitor with anti-inflammatory and antiviral activities. It inhibits JAK1, JAK2, JAK3, and TYK2 with varying IC50 values. This compound also demonstrates the ability to inhibit HIV-1 driven gene transcription and reduce the proliferation of HIV-1 infected cells, making it suitable for studies related to rheumatoid arthritis and inflammatory bowel disease.
- Selectively inhibits JAK1
- Possesses anti-inflammatory and antiviral properties
- Inhibits HIV-1 driven gene transcription
- Reduces proliferation of HIV-1 infected cells
- Applicable for rheumatoid arthritis research
- Applicable for inflammatory bowel disease research